Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration

• DOI: 10.1007/s11095-018-2438-x
• Publication Date: 2018-06-14T11:33:21Z
• Authors: Alex Karlsson-Parra; Juliana Kovacka; Emilia Heimann; Margareth Jorvid; Sijme Zeilemaker; Sharon Longhurst; Peter Suenaert
• Keywords: Cross-Presentation; Immunosurveillance

Intratumoral administration of an immune primer is a therapeutic vaccine strategy aimed to trigger dendritic cell (DC)-mediated cross-presentation cell-associated tumor antigens cytotoxic CD8+ T cells without the need for antigen characterization. The prevailing view that these cross-presenting DCs have be directly activated by pathogen-associated molecular patterns (PAMPS), including Toll-like receptor ligands or live microbial agents like oncolytic viruses. Emerging data are however challenging this view, indicating machinery in suboptimally direct PAMP recognition, and endogenous inflammatory factors main drivers DC-mediated within tumor. Here we present preclinical mode action data, CMC regulatory as well initial clinical on ilixadencel. This cell-based drug product off-the-shelf primer, consisting pro-inflammatory allogeneic secreting high amounts chemokines cytokines at time intratumoral administration. mechanism ilixadencel induce recruitment activation cells, NK subsequently promotes co-recruited DCs.